Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production

Despite recent therapeutic advancements, multiple myeloma (MM) remains incurable and new therapies are needed, especially for the treatment of elderly and relapsed/refractory patients. We have screened a panel of 100 off-patent licensed oral drugs for anti-myeloma activity and identified niclosamide...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanim, F L, Merrick, B A M E, Giles, H V, Jankute, M, Jackson, J B, Giles, L J, Birtwistle, J, Bunce, C M, Drayson, M T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255256/
https://www.ncbi.nlm.nih.gov/pubmed/22829072
http://dx.doi.org/10.1038/bcj.2011.38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255256/
https://www.ncbi.nlm.nih.gov/pubmed/22829072
http://dx.doi.org/10.1038/bcj.2011.38

Ejemplares similares